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Background:Critically ill patients are at high risk for acquiring Clostridium difficile infection.
The aim of this study was to investigate the prevalence, severity, and outcome of neuroin-
tensive care unit (NICU) acquired Clostridium difficile associated disease (CDAD).
Materials andMethods: Intensive care admission and hospital infection control databases
from April 2008 to August 2010 were studied and the case notes reviewed retrospectively.
Diarrhea was classified as mild, moderate, or severe based on the frequency and vol-
ume. Information on demographics, risk factors for CDAD, presentation, and course of the
disease was gathered. Admission diagnosis, days of NICU stay, and incidence of compli-
cations were noted.
Results: In the time period studied, 9 out of 2212 patients (prevalence rate 0.4%) admitted
to the intensive care unit (ICU) for a total of 10,825 bed days (incidence rate 8.3 per 10,000
bed days) acquired CDAD. Median age was 55 (IQR 20–72) years. The median NICU stay
was 26 (IQR 11–103) days.The median duration between ICU admission and development
of CDAD was 11 (IQR 3–93) days. Four patients (44%) had moderate CDAD. Concurrent
infections occurred in seven (77%) patients.The most frequently prescribed antimicrobials
prior to CDAD were cephalosporins (71%).The apparent risk factors in this group included
age >65 year (22%) and antibiotics (67%) among others. One patient developed CDAD
colitis. Three patients had a perceived delay in discharge from the ICU (1–8 days) due to
their infective status. No mortality was ascribed to CDAD.
Conclusion: The prevalence rate (0.4%) and morbidity of CDAD in the unit are low. A
larger database is needed to better analyze the associated risk factors in this subgroup of
patients. A possible increase in disease burden due to a delay in discharge from the ICU
merits further evaluation.
Keywords: Clostridium difficile, Clostridium infections, neurocritical care, nosocomial infections, toxin A, toxin B,
pseudomembranous colitis
INTRODUCTION
Clostridium difficile infection (CDI) and Clostridium difficile asso-
ciated disease (CDAD) is a serious, infectious complication in
hospitalized patients. There has been a progressive rise in the inci-
dence, severity, and complications due to CDAD globally over the
recent years (Kenneally et al., 2007; Marra et al., 2007).
In the intensive care unit (ICU), CDAD is one of the most
important causes of nosocomial infection and has been suggested
to be responsible for a 6% incremental increase in the risk of attrib-
utable mortality (Kenneally et al., 2007). Although more data is
now emerging on CDAD acquired in the general ICU, the infor-
mation from sub specialty ICU remains scanty (Musa et al., 2010,
2011; Crabtree et al., 2011).
The suggested risk factors for acquiring C. difficile infection are
prolonged hospital stay, antibiotic usage, advanced age, immuno-
suppression (corticosteroids), indwelling devices, laxative use, and
proton pump inhibitors (Bobo et al., 2011). Some of these may
be more prevalent in the neurointensive care unit (NICU) than in
other wards. The incidence of, risk factors for, and outcomes of
CDAD in this subgroup of patients are poorly studied and remain
unclear with only one previous published study describing the
prevalence and outcome associated with NICU-acquired CDAD
(Musa et al., 2010).
The aim of this study was to assess the epidemiology, clini-
cal course, management, and outcomes of ICU-acquired CDAD
among patients admitted our NICU.
MATERIALS AND METHODS
The center of interest is a tertiary care referral neurosciences cen-
ter in the UK with a catchment population of about five million.
The NICU was upgraded early in 2010 from a 14- to a 20-bedded
setup of which 16 are level 3 beds equipped for patients of multi-
organ failure who may require advanced respiratory support. This
includes eight isolation rooms where colonized or infected patients
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are managed. The high dependency area has four level two beds
which are occupied by patients requiring basic cardiopulmonary
support or admitted for management of a single organ failure.
The nurse to patient ratio for ICU beds is 1:1 and for the high
dependency area is 1:2. Hand hygiene with soap and water or alco-
hol hand gel and personal protective equipment such as gloves
and plastic aprons are routinely practiced for all patients before
and after contact. Regular audits of hand hygiene practice and
environmental standards are carried out by the infection control
team.
Contact isolation policy in our unit is stringent with immediate
isolation of patients who fulfill Bristol stool five or greater into an
isolation room without awaiting confirmation of infection by the
stool toxin assay. Removal of an infected patient from isolation
after completion of the treatment period requires a symptom free
interval and is a multidisciplinary decision involving the NICU
team, the clinical microbiologist, and the infection control team.
Intensive care unit-acquired CDI was defined by the infec-
tion control team as any of the following-watery or unformed
stools, according to the Bristol stool chart (Lewis and Heaton,
1997), occurring ≥48 h after ICU admission with a laboratory
confirmation of a stool sample positive for C. difficile toxin A or
B, toxic megacolon, or ileotomy where the specimen is C. diffi-
cile toxin positive, pseudomembranous colitis revealed by lower
gastro-intestinal endoscopy or Computed Tomography, colonic
histopathology characteristic of C. difficile infection (with or with-
out diarrhea or toxin detection) on a specimen obtained during
endoscopy or colectomy or fecal specimens collected post-mortem
where the specimen is C. difficile toxin positive or tissue speci-
mens collected post-mortem where pseudomembranous colitis is
revealed or colonic histopathology is characteristic of C. difficile
infection.
The microbiological diagnosis was made by enzyme
immunoassay (EIA). A positive EIA result was confirmed by a
positive glutamate dehydrogenase test (C. diff Quik Chek, Techlab)
and also a positive toxin test (Tox A/B Quik Chek, Techlab).
The UK’s Health Protection Agency (HPA) definitions for
diarrhea and disease severity were used to classify the disease
(Table 1).
The infection control database and microbiology laboratory
records from April 2008 to August 2010 were investigated to
identify patients with CDI. The infection control team in the
hospital maintains a prospective database. The surveillance for
CDI includes the collection of patient details for each episode
such as the hospital number, date of birth, and sex, as well as
information concerning the patient’s location, date of admission,
and care details at the time the fecal sample was taken. Every
quarter the data collected in the enhanced surveillance is used to
produce epidemiological data. In patients with multiple admis-
sions to the NICU, only the first admission was used for analysis.
Data on age, gender, date of admission to NICU, diagnosis, date
of diagnosis of CDI, and APACHE II score were collected. The
presentation, disease severity, course of disease, and complica-
tions such as colitis or time delay in discharge from ICU due to
non-availability of isolation beds in receiving areas if any were
noted.
The number of stool samples submitted for microbiological
examination, the choice of specific antibiotic treatment for the
CDAD, discontinuation or otherwise of ongoing antibiotics, and
the need for more than a single course of treatment were noted.
Potential risk factors associated with CDI including use of antibi-
otics, laxatives, anti-secretory drugs, systemic corticosteroid use,
and invasive lines were recorded when the exposure was prior to
the diagnosis of disease. Other causes of sepsis prior to CDAD
were recorded.
Incidence rates of NICU-acquired CDAD infection were calcu-
lated as the number of cases of NICU-acquired CDAD after 48 h
in intensive care divided by the total number of bed days in the
study period multiplied by 10,000.
The prevalence rate was calculated as the number of NICU-
acquired cases during the study period divided by the total number
of NICU admissions in the study period.
All treatment for CDAD was made after discussion with a
medical microbiologist including duration and discontinuation
or otherwise of systemic antibiotics.
The audit was registered and approved as per institute policy
which waived institute review board and patient consent in view
of the nature of the study.
Table 1 | Grading of severity of C. difficile infection.
Criteria Mild Moderate Severe
Number of liquid stools per day <4 5–7 >8
Fever None 37.5–38.5 °C >38.6 °C
Abdominal symptoms None Severe abdominal pain Signs and symptoms of peritonism
Serum albumin Normal Normal Low <25 g/l
Complications None Lower GI hemorrhage with stable
blood pressure
Lower GI hemorrhage with unstable blood
pressure
Perforation of colon
Sepsis due to colitis
Renal dysfunction (50% above baseline)
Elevated serum lactate (2.2–4.9 mmol/l)
Peripheral white cells Normal 10–15×109/l >15×109/l
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RESULTS
INCIDENCE AND PREVALENCE OF CDAD
In the study period, nine patients acquired CDAD after 48 h of
admission. A total of 2212 patients were admitted to the NICU
in this period with 10,825 bed days, giving a CDAD infection
incidence rate of 8.3 per 10,000 days and a prevalence of 0.4%.
PATIENT CHARACTERISTICS
Three out of the nine patients were male (Table 2). The median
age of the CDAD patients was 55 (20–72) years, with two patients
>65 years of age. All of the CDAD cases were emergency admis-
sions of which eight were neurosurgical patients and one was a
neurology patient. Patients had a mean 6.7 (±5.2) days of diarrhea
prior to a positive assay, with a median of 3 (1–7) stool samples
having been sent for toxin assay.
IDENTIFIED RISK FACTORS FOR CDAD
Risk factors for CDAD included age >65 – 2 of the nine patients
were >65 years age, antibiotics were administered to 7/9 (77%),
laxatives, and proton pump inhibitors to all the patients as per
the unit protocol (100%), steroids to 3/9 (33%), and indwelling
medical device was required in all patients (100%). Seven of the
nine patients (77%) had received mechanical ventilation prior to
diagnosis for a median period of 20 (8–96) days.
One of the patients grew the highly virulent strain NAP1/BI/027
of C. difficile on culture – the others being (001, 018, and 014/020).
ANTIBIOTIC USAGE
Seven (77%) of the patients had received some antibiotic prior to
the diagnosis of CDAD. In two patients this was a single dose of
Table 2 | Characteristics of patients with Clostridium difficile
associated disease in the NICU.
Characteristic n %/IQR
Age (IQR) 55 20–72
Male gender (%) 3 33
APACHE II (IQR) 20 11–32
Days in unit (IQR) 26 11–103
Days on ventilator (IQR) 20 8–96
Severity of cdad
Mild 2 22
Moderate 4 44
Severe 3 33
Days from admission to
diagnosis (IQR)
11 3–93
Treatment (n=9/%)
Nothing 0
Metronidazole 4
Vancomycin 2
Both 3
Morbidity (colitis on CT
scan)
1
Total mortality (n=9) 4 (44%)
Mortality attributable to
CDAD
0
surgical prophylaxis (McDonald et al., 1998). The most frequently
prescribed antimicrobials prior to CDAD were cephalosporins
(71%), Piperacillin/Tazobactam (28%), Vancomycin (28%), gen-
tamicin (14%), and Meropenem (14%).
CONCURRENT INFECTION
Concurrent infections which were considered clinically significant
to warrant treatment occurred in seven (77%) of the patients, three
of which were ventilator associated pneumonia, four meningitis,
and one septicemia. Pseudomonas species was the organism iso-
lated most often (43%), followed by methicillin sensitive Staphy-
lococcus aureus (28%), Enterococcus sp. (28%), and Klebsiella sp.
(14%).
COURSE OF DISEASE AND TREATMENT
At presentation, temperature >38.3 °C and WCC >15,000/cc was
present in 3/9 (33% of patients. The mean serum albumin was
2.2 g/dl. All patients by definition had free stools of Bristol chart
type 5 or more (stool taking the shape of the container).
Septic shock, respiratory failure, and liver failure not directly
related to CDAD occurred in four, six, and two patients respec-
tively.
Both the patients with mild and two with moderate CDAD
improved with a course of oral metronidazole of 14 days. Two
patients with moderate CDAD received a course of oral metron-
idazole followed by treatment with nasogastric vancomycin. All
three patients with severe CDAD were treated with nasogastric
vancomycin for 21 days two of whom relapsed and required a
further course of nasogastric vancomycin.
Three patients (33%) had a perceived delay in discharge from
NICU (ranging 1–8 days) due to CDAD infective status.
MORBIDITY AND MORTALITY
One patient developed CDAD colitis (CT scan positive for bowel
wall thickening and stranding); there were no cases of bowel per-
foration or GI hemorrhage directly attributable to CDAD. Of a
total mortality of 4/9 cases, there was no mortality attributable to
CDAD.
DISCUSSION
Clostridium difficile associated disease is an important hospital-
acquired infection among critically ill patients. The basic patho-
genesis involves the disturbance of the normal colonic microbial
flora by antibiotics. This promotes the conversion of the C. diffi-
cile spore to a vegetative form and encourages the production of
toxins. The usual presentation is diarrhea, which may be accompa-
nied with abdominal pain, hypotension, electrolyte perturbations,
and fever (Loo et al., 2005).
There is a wide variation in the reporting of Clostridium infec-
tions among the published studies. CDAD is more common with
in the general intensive care setting with an overall incidence and
prevalence as high as 54 per 10,000 patient days and 7% respec-
tively (Lawrence et al., 2007; Scott et al., 2012). In the pediatric
ICU, Pinto (2012) have reported a CDAD prevalence of 1.5%.
Among the limited reports of CDAD in subgroups of ICU
patients, Musa et al. (2011) and Musa et al. (2010) have reported
the prevalence of CDAD infection in the NICU as 0.6 and 0.5%
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in the cardiothoracic unit. Crabtree et al. (2011) in their study
report an incidence of 7.2 per 10,000 patient days in the burns
ICU (BICU) and 15.5 infections in 10,000 patient days among
patients in the non-BICU in spite of longer duration of stay and
greater number of surgical interventions in the BICU patients who
were more often young males. The rates of infection in our patients
appear to be lesser than those in general ICUs and similar to the
ICUs catering to patient subgroups.
Similar to the findings of Musa et al. (2010) we had a greater
proportion of emergency admissions, post-surgical patients and
had a similar median age of patient population infected with
similar severity of illness at admission (APACHE II scores).
The three major risk factors for CDAD are the use of antibi-
otics, advanced age, and prolonged hospitalization (Loo et al.,
2005) (Table 3). A single-dose surgical antibacterial prophylaxis
suffices to increase the risk of CDAD. Exposure to all antimi-
crobial classes is implicated with fluoroquinolones leading the
list (Pépin et al., 2005; Carignan et al., 2008). Cephalosporin
use is common in our unit for treatment and surgical prophy-
laxis due to their desirable CSF penetration and most of our
patients 7/9 had received cephalosporin group of antibiotic at least
once.
The incidence, complications, and recurrence of CDAD among
individuals aged >65 years may be up to 10 times higher than
among younger adults (McDonald et al., 2006; Garey et al., 2008).
Only two patients in our cohort were >65 years of age, and this
may explain the lower incidence and complications. It has been
argued that the prolonged length of stay in the ICU for these
patients could be the reason rather than the consequence of CDAD
(Wanahita et al., 2003).
The Canadian and English outbreaks of CDAD were related
to the more virulent subtype-NAP1/BI/027. The one patient in
our cohort infected with this strain developed CDAD colitis and
required prolonged treatment with nasogastric vancomycin.
As in other such studies, a low number of patients with CDAD
in our group does preclude meaningful statistical analysis, since
it may show spurious associations. The findings can only be pre-
sented in a descriptive form. A larger prospectively designed study
is needed wherein regression analysis can be performed to analyze
the risk factors associated with patients in NICU when compared
to general ICU patients. Clinical signs and symptoms of CDAD
include non-specific ones of diarrhea, abdominal distention, leu-
cocytosis, and fever. All our patients being on laxatives, and most
having concurrent infections, could have influenced our catego-
rization of disease severity and may have led to over treatment in
some cases.
Table 3 | Risk factors associated with CDAD [34].
Perturbation of the intestinal
flora/mucosa or immune system
Antibiotic treatment
Fluoroquinolone-resistant
BI/NAP1/027
Proton pump inhibitors-receptor
antagonists
Chemotherapy (hematopoietic and
H2 stem cell and solid organ
transplants)
Glucocorticoids
Radiation treatment
Intestinal stasis (medications)
Abdominal surgery
Nasogastric tubes and enemas
Environmental contamination Length of stay in hospital or
long-term care facility
Possible: food contamination, pets,
and farm animals
Host factors Age >65 years
Multiple comorbidities
Peripartum women and children
Inflammatory bowel disease
HIV
Chronic kidney disease requiring
hemodialysis
In conclusion, the rates of infection and morbidity in our
unit are acceptably low. Among other preventive measures, early
stool sampling, and isolation, repeated sampling in continued
diarrhea of uncertain cause and initiating vancomycin in severe
infections as followed in our unit may be of particular bene-
fit. A high ratio of isolation beds to beds in a common space
(ratio 8 side room beds:12 common beds) could be another fac-
tor helping prevent cross infection. There is a need for a larger
database and greater uniformity in reporting CDAD infections
in ICUs catering to special patient groups to better compare
and understand the risk factors, design tailored severity scoring
and lay down discharge criteria of patients with CDI from the
NICU.
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